Bruker (BRKR) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bruker (BRKR) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 19.4% versus a loss of 26.6%. Over five years, BRKR leads with a -32.2% price change compared with -93.0% for PACB. Bruker is the larger company by market cap ($8.62 billion vs $508.9 million), about 16.9 times the size, while Pacific Biosciences of California is growing revenue faster (+3.9% vs +2.1%).
Bruker pays a dividend yielding 0.09%, while Pacific Biosciences of California does not currently pay one. Bruker converts more of its revenue into profit, with a net margin of -0.3% versus -341.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRKR | PACB |
|---|---|---|
| Share price | $56.46 | $1.63 |
| Market cap | $8.62B | $508.95M |
| 1-day change | -9.08% | -7.39% |
| YTD return | +19.85% | -12.83% |
| 1-year return | +19.44% | -26.58% |
| 5-year return | -32.16% | -93.01% |
| Forward P/E | 23.25 | — |
| EPS (TTM) | $-1.10 | $-0.42 |
| Dividend yield | 0.09% | 0.00% |
| Annual dividend | $0.05 | $0.00 |
| Revenue (latest FY) | $3.44B | $160.00M |
| Revenue growth (YoY) | +2.08% | +3.89% |
| Net income (latest FY) | $-8.60M | $-546.38M |
| Gross margin | 45.91% | 28.61% |
| Operating margin | 1.98% | -346.15% |
| Net margin | -0.25% | -341.47% |
| 52-week high | $68.98 | $3.44 |
| 52-week low | $32.37 | $1.07 |
| Distance from 52-week high | -18.15% | -52.62% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +20.44% | +68.10% |
| Average volume | 2.32M | 13.23M |
| Shares outstanding | 152.72M | 312.24M |
| Employees | 11,085 | 485 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bruker is about 16.9 times larger than Pacific Biosciences of California by market value ($8.62B vs $508.95M).
- BRKR has outperformed PACB by 46.0 percentage points over the past year.
- Bruker is more profitable, keeping -0.3 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.
About Bruker
BRKR stock →Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
BRKR vs PACB FAQ
Which is bigger, Bruker or Pacific Biosciences of California?
Bruker (BRKR) is larger, with a market capitalization of $8.62B compared with $508.95M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, BRKR or PACB?
BRKR returned +19.44% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bruker or Pacific Biosciences of California?
Bruker pays a dividend yielding 0.09%, while Pacific Biosciences of California does not currently pay a regular dividend.
Are Bruker and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.